Who are Disitamab vedotin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tivdak, Tisotumab Vedotin, LONCASTUXIMAB TESIRINE, Besponsa, Kadcyla, Mylotarg.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/disitamab-vedotin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Disitamab vedotin — Competitive Intelligence Brief

Disitamab vedotin (disitamab-vedotin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: antibody-drug conjugate. Area: Oncology.

marketed antibody-drug conjugate human epidermal growth factor receptor 2 (HER2) Oncology Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Disitamab vedotin (disitamab-vedotin) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Disitamab vedotin TARGET	disitamab-vedotin	Pfizer	marketed	antibody-drug conjugate	human epidermal growth factor receptor 2 (HER2)
Tivdak	tisotumab-vedotin	SEAGEN	marketed	Antibody-drug conjugate	Tissue factor	2021-01-01
Tisotumab Vedotin	tivdak	SEAGEN	marketed	Antibody-Drug Conjugate (ADC)	Tissue factor	2021-01-01
LONCASTUXIMAB TESIRINE	LONCASTUXIMAB TESIRINE		marketed	Antibody-Drug Conjugate (ADC)	CD19	2021-01-01
Besponsa	inotuzumab-ozogamicin	Pfizer	marketed	Antibody-drug conjugate (ADC)	CD22	2017-01-01
Kadcyla	trastuzumab-emtansine	Roche	marketed	Antibody-drug conjugate	Receptor tyrosine-protein kinase erbB-2	2013-01-01
Mylotarg	Gemtuzumab Ozogamicin	Pfizer	marketed	Antibody-drug conjugate (ADC)	CD33 antigen	2000-01-01

Recent regulatory actions (last 90 days)

2026-03-26 — Kadcyla · FDA · approved · US · Roche
2026-02-20 — LONCASTUXIMAB TESIRINE · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (antibody-drug conjugate class)

Merck Sharp & Dohme LLC · 1 drug in this class
Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Disitamab vedotin — Competitive Intelligence Brief. https://druglandscape.com/ci/disitamab-vedotin. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab